anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

129,301-129,360 of 319,975

filter-aware
166
The slide uses a scientific table to challenge the 'no appreciable binding' claim found in a drug's package insert, citing reproducibility concerns regarding the source of that claim.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
168
The slide uses specific case descriptions to argue for a pattern of respiratory/pulmonary-related deaths.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
169
The slide uses a direct quote from an FDA clinical review to demonstrate a lack of oversight regarding a specific medical signal.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
172
The slide uses a specific medical case study to establish a pattern of misdiagnosis and severity, linking it to the current subject (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
173
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
174
The slide argues that reporting lags or manipulation by Harmony Biosciences obscures the true number of adverse events.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
175
The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
176
The slide highlights specific medical conditions and counts of adverse event reports from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
177
The slide highlights a potential contradiction between marketing claims of 'no dependency' and reported withdrawal symptoms.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
178
The slide highlights a potential discrepancy between official FDA reporting and actual event timing, suggesting either database lag or manufacturer reporting delays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
179
The slide uses a 'back-of-the-envelope' calculation to argue that reported adverse events are undercounted.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
180
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
181
The slide presents a clinical case narrative alongside screenshots of FDA FAERS database records.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
182
This is a clinical case report document, likely from an FDA FAERS FOIA request.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
183
The slide presents a clinical case study narrative, likely for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
184
The slide highlights a potential cover-up or reporting discrepancy regarding a patient seizure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
185
The slide presents a narrative summary of a medical case report, pointing out suspicious physician/company behavior regarding the reporting of heart palpitations.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
186
The slide presents a clinical case study from the FDA FAERS database, highlighting a potential drug-drug interaction or confounding factor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
187
This is a clinical case report document from the FDA Adverse Event Reporting System (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
188
This is a raw FDA FAERS FOIA case report document.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
189
The slide presents a clinical case study analysis of a specific adverse event report (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
190
This slide presents raw clinical case data from the FDA FAERS database to support a hypothesis about drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
191
The slide highlights a discrepancy between patient belief and sponsor assessment regarding drug causality.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
192
The slide highlights a specific safety concern regarding pitolisant (Wakix) and its interaction with CYP2D6 inhibitors.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
193
The slide uses a narrative structure to expose a potential cover-up or reporting failure regarding a serious adverse event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
194
This is a medical case report summary, likely used for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
195
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
196
The slide presents a specific pharmacovigilance case report, highlighting a positive dechallenge.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
197
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
198
This appears to be a medical case report document from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
199
This is a clinical case study/adverse event report sourced from FDA FAERS data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
200
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
201
The slide presents a patient-reported adverse event (FAERS) to challenge the safety profile of a pharmaceutical product.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
203
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
204
The slide highlights a discrepancy between the drug's safety profile as presented and the real-world experience of a physician.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
205
The slide presents a qualitative case study (anecdotal evidence) regarding a potential adverse drug event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
206
The slide highlights specific clinical symptoms and diagnostic procedures (EKG, cardiac enzymes, telemetry) used to rule out cardiac issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
207
The slide uses a Q&A format to document a specific interaction between a doctor and a pharmaceutical sales representative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
208
Harmony Biosciences (HRMY)Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
210
The slide uses a table of clinical trials alongside red-text annotations to highlight the geographic and temporal distance of the studies.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
212
The slide uses a pie chart to highlight that 38% of study participants were in Russia, suggesting a lack of geographic diversity and potential data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
213
The slide uses a combination of narrative text and specific evidence (EMA table and ClinicalTrials.gov record) to prove the existence of a suppressed trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
215
The slide functions as a 'fraud-exposure' or 'villain-critique' framework, systematically dismantling the credibility of the clinical trial data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
216
This slide serves as a critical audit of clinical trial integrity, focusing on statistical manipulation and poor trial design.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
221
The slide uses clinical trial data to undermine the efficacy claims of a drug by highlighting the placebo response.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
222
The slide uses FDA biometrics review data to challenge the efficacy timeline of the drug Wakix (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
223
The author argues that the discrepancy hides a trend reversal that would undermine the trial's efficacy claims.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
224
The slide uses a 'red flag' argument to suggest data manipulation or p-hacking via sample size adjustment.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
225
The slide uses a strong, accusatory tone to undermine the validity of the clinical trial results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit